Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GIPR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GIPR ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View GIPR Products |
| Gene Delivery | GIPR Promise-ORF / Lentivirus. Full-length GIPR ORF in lentiviral particles for stable cell line generation. Preserves native Class B GPCR conformation and 7-TM topology. | View GIPR Products |
| Benchmark Ab | Anti-GIPR Recombinant Antibody (Benchmark Format). Sequence-verified positive control for binding and functional assays. | View GIPR Products |
| Validator | GIPR siRNA Set. For knockdown verification and assay specificity confirmation. | View GIPR Products |
| Related Target A | GLP-1R. Synergistic incretin pathway target; essential for dual/triple agonist development. | View GLP-1R Products |
| Related Target B | GCGR. Glucagon receptor partner for next-generation metabolic poly-agonists. | View GCGR Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Cyno/Mouse ortholog proteins available with >95% purity. Sequence verified by Mass Spec for toxicology bridging studies. |
| Multi-receptor selectivity (vs GLP-1R/GCGR) | High-purity homolog panel (GIPR, GLP-1R, GCGR) strictly verified by mass spec for off-target liability assessment. |
| Full-length GPCR conformational integrity | Lentivirus-mediated stable cell lines preserve native multi-transmembrane GPCR structure and 7-TM topology for functional assays (cAMP/Calcium flux). |
| Lack of reliable controls | Research-grade benchmark antibodies and validated siRNA included for assay standardization. |
| In vitro false positives | Validated siRNA and negative-control lentivirus included for specificity checks in cell-based signaling assays. |
Live GIPR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The GIPR (Gastric Inhibitory Polypeptide Receptor) has re-emerged as a central node in metabolic disease therapeutics, driven by the clinical validation of dual GIPR/GLP-1R agonists (tirzepatide) and triple agonists (retatrutide). The landscape is rapidly shifting from single-target GLP-1R agonists to nuanced multi-receptor modulation, with GIPR agonism now viewed as essential for superior glycemic control and weight loss efficacy. A unique pharmacological divergence has emerged, with developers exploring both GIPR agonism and GIPR antagonism in combination with GLP-1R activation to drive superior metabolic profiles. Next-generation candidates are exploring biased signaling to optimize G-protein activation while minimizing β-arrestin recruitment to delay receptor desensitization. The next wave of R&D is targeting highly engineered peptides, bispecific antibodies, antibody-peptide conjugates, and small molecules, demanding exceptionally precise in vitro assay systems for cross-reactivity profiling, species-relevant evaluation, and signaling bias analysis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Dual Agonist (GIPR/GLP-1R) | Eli Lilly (Tirzepatide) | Obesity, Type 2 Diabetes | Bias signaling assay (cAMP vs β-arrestin); Cross-reactive protein panel |
| Triple Agonist (GIPR/GLP-1R/GCGR) | Eli Lilly (Retatrutide) | Severe Obesity, NASH | Triple selectivity assay; Human/Cyno cross-reactivity validation |
| GIPR Antagonist + GLP-1 Agonist (Bispecific) | Amgen (AMG 133) | Obesity | Receptor internalization assay; Blockade efficacy screening |
| Small Molecule / Biased Ligand | Roche, Viking Therapeutics, Structure Therapeutics | Metabolic Syndrome, Oral Obesity Tx | Selectivity assay (mutant vs WT GIPR; homolog panel) |
| Peptide Conjugates | Various Biotechs | Metabolic Disorders | Stability assay; pH-dependent binding analysis |